Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

279 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit.
Triulzi T, Regondi V, De Cecco L, Cappelletti MR, Di Modica M, Paolini B, Lollini PL, Di Cosimo S, Sfondrini L, Generali D, Tagliabue E. Triulzi T, et al. Among authors: de cecco l. Br J Cancer. 2018 Dec;119(12):1487-1494. doi: 10.1038/s41416-018-0318-0. Epub 2018 Nov 27. Br J Cancer. 2018. PMID: 30478407 Free PMC article.
Molecular portrait of breast cancer in China reveals comprehensive transcriptomic likeness to Caucasian breast cancer and low prevalence of luminal A subtype.
Huang X, Dugo M, Callari M, Sandri M, De Cecco L, Valeri B, Carcangiu ML, Xue J, Bi R, Veneroni S, Daidone MG, Ménard S, Tagliabue E, Shao Z, Wu J, Orlandi R. Huang X, et al. Among authors: de cecco l. Cancer Med. 2015 Jul;4(7):1016-30. doi: 10.1002/cam4.442. Epub 2015 Mar 18. Cancer Med. 2015. PMID: 25787708 Free PMC article.
Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration.
Triulzi T, De Cecco L, Sandri M, Prat A, Giussani M, Paolini B, Carcangiu ML, Canevari S, Bottini A, Balsari A, Menard S, Generali D, Campiglio M, Di Cosimo S, Tagliabue E. Triulzi T, et al. Among authors: de cecco l. Oncotarget. 2015 Sep 29;6(29):28173-82. doi: 10.18632/oncotarget.4405. Oncotarget. 2015. PMID: 26334217 Free PMC article.
CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers.
Turdo F, Bianchi F, Gasparini P, Sandri M, Sasso M, De Cecco L, Forte L, Casalini P, Aiello P, Sfondrini L, Agresti R, Carcangiu ML, Plantamura I, Sozzi G, Tagliabue E, Campiglio M. Turdo F, et al. Among authors: de cecco l. Oncotarget. 2016 Oct 25;7(43):69649-69665. doi: 10.18632/oncotarget.11935. Oncotarget. 2016. PMID: 27626701 Free PMC article.
279 results